This Company's Co-CEOs Just Bought More Shares. Should You?

Nobody has more information about a company than its insiders, especially its executive management team. That's why when one of them buys more shares, it sometimes gives individual investors insights into the company's prospects. If those with the most knowledge think it's worth loading up on the stock, maybe other investors do the same -- or so the argument goes.That brings us to Summit Therapeutics (SMMT 8.47%), a clinical-stage biotech whose co-chief executive officers recently bought more shares of the ...